Literature DB >> 4985377

The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines.

M R Hilleman.   

Abstract

The major antigenic changes in influenza A virus that occur at 10-year intervals reduce the effectiveness of existing vaccines and pose a problem for the control of pandemics by vaccination. These difficulties may be obviated in two ways. First, by detecting the emergence of a new variant sufficiently ahead of its general spread for it to be possible to produce a corresponding vaccine in good time; the World Health Organization is widely depended upon for this early warning. Secondly, by the improvement of existing vaccines to increase and broaden their antigenicity; here, their modification by, for instance, adjuvant 65 may contribute significantly.

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4985377      PMCID： PMC2427699     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  11 in total

1.  NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. I. DEVELOPMENT AND ANIMAL IMMUNE RESPONSE.

Authors:  A F WOODHOUR; D P METZGAR; T B STIM; A A TYTELL; M R HILLEMAN
Journal:  Proc Soc Exp Biol Med       Date:  1964-06

2.  New metabolizable immunologic adjuvant for human use. IX. Large-scale trials with multiple lots in different regimens.

Authors:  J Stokes; R E Weibel; A F Woodhour; W J McAleer; L A Potkonski; M R Hilleman
Journal:  JAMA       Date:  1969-03-17       Impact factor: 56.272

3.  New metabolizable immunologic adjuvant for human use. 8. Chronic toxicity and teratogenic tests.

Authors:  H M Peck; A F Woodhour; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1968-07

4.  Hyperpotentiation by synthetic double-stranded RNA of antibody responses to influenza virus vaccine in adjuvant 65.

Authors:  A F Woodhour; A Friedman; A A Tytell; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1969-07

Review 5.  Critical appraisal of emulsified oil adjuvants applied to viral vaccines.

Authors:  M R Hilleman
Journal:  Prog Med Virol       Date:  1966

6.  Antibody response in man to Hong Kong influenza following 1967 formula influenza vaccine in adjuvant 65.

Authors:  A F Woodhour; W J McAleer; A Friedman; R E Weibel; J Stokes; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

7.  New metabolizable immunologic adjuvant for human use. 4. Development of highly purified influenza virus vaccine in adjuvant 65.

Authors:  A F Woodhour; D P Metzgar; G P Lampson; R A Machlowitz; A A Tytell; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1966-12

8.  New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus vaccine in adjuvant 65.

Authors:  R E Weibel; A F Woodhour; J Stokes; D P Metzgar; M R Hilleman
Journal:  N Engl J Med       Date:  1967-01-12       Impact factor: 91.245

9.  New metabolizable immunologic adjuvant for human use. 6. Disposition of radioactivity after administration of labelled vaccine to the rat.

Authors:  C C Porter; D C Titus
Journal:  Proc Soc Exp Biol Med       Date:  1967-02

10.  NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 3. EFFICACY AND TOXICITY STUDIES IN MAN.

Authors:  J STOKES; R E WEIBEL; M E DRAKE; A F WOODHOUR; M R HILLEMAN
Journal:  N Engl J Med       Date:  1964-09-03       Impact factor: 91.245
View more
  1 in total

1.  Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968.

Authors:  Barbara J Jester; Timothy M Uyeki; Daniel B Jernigan
Journal:  Am J Public Health       Date:  2020-05       Impact factor: 9.308
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.